Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease Without Mechanical Valves
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.035478 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Ghadeer K Dawwas und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Epidemiology Vanderbilt University School of Medicine Nashville TN. Hauptthemen laut MEDLINE: Atrial Fibrillation, Warfarin, Heart Valve Diseases, Anticoagulants. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Background
Despite proven efficacy and safety of direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), data on patients with AF and valvular heart disease remain scarce. We aimed to evaluate the DOACs compared with warfarin among patients with AF and valvular heart disease. Methods and Results We conducted a retrospective cohort study of patients ≥18 years of age, who had AF and valvular heart disease, and were new users of DOACs or warfarin. The primary effectiveness outcomes were ischemic stroke or systemic embolism, and bleeding for safety. We used Cox proportional‐hazards regression after propensity score matching to estimate hazard ratios (HRs) and 95% CIs. In the matched cohort, DOAC use (versus warfarin) was associated with a lower rate of ischemic stroke or systemic embolism (HR, 0.70 [95% CI, 0.61–0.81]) and bleeding (HR, 0.72 [95% CI, 0.65–0.80]). We found a lower rate of ischemic stroke or systemic embolism with rivaroxaban (HR, 0.74 [95% CI, 0.62–0.89]) and apixaban (HR, 0.62 [95% CI, 0.52–0.74]) but not dabigatran (HR, 0.89 [95% CI, 0.63–1.26]). We found a lower rate of bleeding with rivaroxaban (HR, 0.84 [95% CI, 0.74–0.95]), apixaban (HR, 0.60 [95% CI, 0.53–0.68]), dabigatran (HR, 0.75 [95% CI, 0.58–0.97]), and edoxaban (HR, 0.21 [95% CI, 0.05–0.83]). We were unable to obtain estimates for the effectiveness outcome with edoxaban due to the small number of events.
Conclusions
In this study of patients with AF and valvular heart disease, DOAC treatment was associated with a lower risk of ischemic stroke or systemic embolism and bleeding compared with warfarin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Epidemiology Vanderbilt University School of Medicine Nashville TN.
- Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine University of Pennsylvania Philadelphia PA.
- Division of Gastroenterology and Hepatology, Perelman School of Medicine University of Pennsylvania Philadelphia PA.
- Department of Medicine and Department of Pathology & Laboratory Medicine, Perelman School of Medicine University of Pennsylvania Philadelphia PA.
ORCID-Profile: Ghadeer K Dawwas, James D Lewis, Adam Cuker
Förderung
- NHLBI NIH HHS
Zitieren
APA
Dawwas, G. K., Lewis, J. D., & Cuker, A. (2025). Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease Without Mechanical Valves. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.035478
Vancouver
Dawwas GK, Lewis JD, Cuker A. Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease Without Mechanical Valves. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.035478
BibTeX
@article{Dawwas2025,
author = {Dawwas, Ghadeer K and Lewis, James D and Cuker, Adam},
title = {Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease Without Mechanical Valves},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.035478}
}
EUVIMED